Therapeutic Response and Disease Progression

Patients with idiopathic pulmonary fibrosis are at a higher risk of certain cardiovascular diseases.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Interclass biologic switching can improve outcomes, but it also increases infection rates.

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Zongertinib gains FDA approval for treating HER2-mutated non–small cell lung cancer (NSCLC), offering hope with fewer side effects and promising response rates in patients.

The FDA approved multiple groundbreaking treatments in July, enhancing options across patient populations.